Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7029451 | 0.87 | PTGS1 (0.43) | PTGS2 | |
| SCHEMBL7024957 | 0.85 | PTGS2 (0.49) | PTGS2 | |
| SCHEMBL7254588 | 0.85 | PTGS2 (0.47) | PTGS2 | |
| SCHEMBL5708983 | 0.81 | PTGS2 (0.67) | PTGS2 | |
| SCHEMBL7259908 | 0.81 | PTGS2 (0.46) | PTGS2ALDH1A1 | |
| SCHEMBL7254196 | 0.81 | MAPK13 (0.39) | PTGS2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL7154393 | 0.79 | MAOA (0.42) | PTGS2 | |
| SCHEMBL7255520 | 0.79 | PTGS2 (0.36) | PTGS2ALDH1A1ESR1AR | |
| SCHEMBL7028615 | 0.73 | RAB9A (0.41) | PTGS2ALDH1A1AR | |
| SCHEMBL7027922 | 0.72 | PTGS2 (0.46) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299372-A1 | PYRONES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA INC. (CA) | 2003-04-09 | — | — | EP | disclosed |
| US-6465509-B2 | FOR THERAPY AND PROPHYLAXIS OF INFLAMMATORY DISEASE SUSCEPTIBLE TO TREATMENT WITH A NON-STEROIDAL ANTI-INFLAMMATORY AGENT | MERCK FROSST CANADA & CO. (CA) | 2002-10-15 | — | — | US | disclosed |
| US-20020058690-A1 | For therapy and prophylaxis of inflammatory disease susceptible to treatment with a non- steroidal anti-inflammatory agent | MERCK FROSST CANADA LTD. (CA) | 2002-05-16 | — | — | US | disclosed |
| WO-2002002547-A1 | PYRONES AS INHIBITORS OF CYCLOOXYGENASE-2 | MERCK FROSST CANADA & CO. (CA) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058690-A1 | For therapy and prophylaxis of inflammatory disease susceptible to treatment with a non- steroidal anti-inflammatory agent | PTGS1, PTGES2, PTGS2 | PTGS2 3/4885MAPK13 3018/4885MAPK12 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.